Safety, Tolerability, Pharmacokinetics, and Metabolism of Telacebec (Q203) for the Treatment of Tuberculosis: a Randomized, Placebo-Controlled, Multiple Ascending Dose Phase 1B Trial

被引:8
|
作者
Kim, Jeongjun [1 ,2 ]
Choi, Jinho [2 ]
Kang, Hwankyu [2 ]
Ahn, Jiye [2 ]
Hutchings, Jane [2 ]
Niekerk, Christo van [2 ]
Kim, Jaeseung [2 ]
Jeon, Yeejin [2 ]
Nam, Kiyean [2 ]
Kim, Tae Hwan [3 ]
Shin, Beom Soo [1 ]
Shin, Soyoung [4 ]
机构
[1] Sungkyunkwan Univ, Sch Pharm, Suwon, Gyeonggi do, South Korea
[2] Qurient Co Ltd, Seongnam, Gyeonggi-do, South Korea
[3] Daegu Catholic Univ, Coll Pharm, Gyongsan, Gyeongbuk, South Korea
[4] Wonkwang Univ, Coll Pharm, Iksan, Jeonbuk, South Korea
关键词
telacebec; multiple ascending doses; antituberculosis; safety; pharmacokinetics; metabolism; DRUG-RESISTANT TUBERCULOSIS; MULTIDRUG-RESISTANT; CLINICAL CANDIDATE; DELAMANID; TIME;
D O I
10.1128/aac.01123-22
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
A phase lb, randomized, placebo-controlled, double-blind, multiple ascending dose study (NCT02858973) was conducted to assess the safety, tolerability, and pharmacokinetics of the new antituberculosis agent telacebec (Q203). A total of 47 healthy adult subjects entered the study; 36 received telacebec, and 11 received placebo. Telacebec at doses of 20, 50, 100, 160, 250, and 320 mg was orally administered once daily with a standard meal for 14 days. Multiple oral doses of telacebec up to 320 mg daily for 14 days appeared to be safe and well tolerated by healthy adult subjects in this study. There were no deaths, serious adverse events, or subject discontinuations due to adverse events. Following oral doses of telacebec, the overall extent (AUC(r)) and peak (C-max) exposures of telacebec increased from 538.94 to 10,098.47 ng.h/mL and from 76.43 to 1502.33 ng/mL, respectively, with increasing telacebec doses from 20 mg to 320 mg. A steady state was achieved for plasma telacebec by day 12, and there was 1.9- to 3.1-fold accumulation in the extent of telacebec exposure after daily doses for 14 days. Analysis of plasma samples from the participants indicated that telacebec was the primary circulating entity with no significant metabolites. Three potential metabolites of telacebec have been identified, which may be relatively minimal compared to the parent drug. Consistent with findings from preclinical and previous single-dose clinical studies, these results also support the potential of telacebec for further development as a safe and effective agent for the treatment of tuberculosis.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alirocumab in Healthy Chinese Subjects: A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study
    Haiyan Li
    Yudong Wei
    Zhenhua Yang
    Shuang Zhang
    Xiuxiu Xu
    Mengmeng Shuai
    Olivier Vitse
    Yiwen Wu
    Marie T. Baccara-Dinet
    Yi Zhang
    Jianyong Li
    American Journal of Cardiovascular Drugs, 2020, 20 : 489 - 503
  • [42] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alirocumab in Healthy Chinese Subjects: A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study
    Li, Haiyan
    Wei, Yudong
    Yang, Zhenhua
    Zhang, Shuang
    Xu, Xiuxiu
    Shuai, Mengmeng
    Vitse, Olivier
    Wu, Yiwen
    Baccara-Dinet, Marie T.
    Zhang, Yi
    Li, Jianyong
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2020, 20 (05) : 489 - 503
  • [43] Safety of biolimus A9 in a double-blinded, placebo-controlled multiple ascending dose trial
    Christians, U.
    Bucher-Bartelson, B.
    Gonzalez, M.
    Reilley, S.
    EUROPEAN HEART JOURNAL, 2007, 28 : 217 - 217
  • [44] A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety, and Tolerability After Subcutaneous Administration of Tozorakimab in Healthy Chinese Participants
    Li, Yunfei
    Zhang, Hua
    Pandya, Hitesh
    Miao, Liyan
    Reid, Fred
    Jimenez, Eulalia
    Sadiq, Muhammad Waqas
    Moate, Rachel
    Lei, Alejhandra
    Zhou, Xiao-Hong
    Kell, Chris
    Ding, Junjie
    Zhang, Guanlin
    Zhao, Lina
    Ge, Xiaoyun
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (06): : 665 - 671
  • [45] Randomized, Double-Blind, Placebo-Controlled Studies of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eravacycline
    Newman, Joseph, V
    Zhou, Jian
    Izmailyan, Sergey
    Tsai, Larry
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (11)
  • [46] A Phase 1b, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 876, a Novel Fc-FGF-21 Fusion Protein, in Subjects with Type 2 Diabetes Mellitus
    Abuqayyas, Lubna
    Tracy, Michael
    Smith, Shawna
    Anderson, Abraham
    Kaufman, Allegra
    DIABETES, 2017, 66 : A282 - A282
  • [47] Safety, Tolerability, and Pharmacokinetics of Nebulized GB05-Human IFNα1b Inhalation Solution: A Randomized, Placebo-Controlled, Dose-Escalation Phase I Study in Healthy Chinese Adult Volunteers
    Peng, Hengxin
    Zhang, Wenjun
    Lin, Yanqing
    Li, Huiming
    Qin, Suofu
    INFECTIOUS DISEASES AND THERAPY, 2024, 13 (09) : 2053 - 2070
  • [48] A randomized, placebo-controlled, dose-escalation, phase 1 study of the safety and pharmacokinetics of amphotericin B inhalation powder in healthy subjects
    Marcantonio, Annette
    Kugler, Alan R.
    Sahner, David
    Mufti, Nina
    Lee, Jonathan D.
    Samford, Lori K.
    Eldon, Michael A.
    BLOOD, 2007, 110 (11) : 324B - 324B
  • [49] A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Ascending Multiple Oral Doses of CC 930 in Healthy Volunteers
    Kong, Linghui
    Ye, Ying
    Liu, Liangang
    Reyes, Josephine
    Wan, Yuntao
    Wu, Anfan
    Lau, Henry
    Laskin, Oscar
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (09): : 1343 - 1343
  • [50] A phase 1, randomized, double-blind, placebo-controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects
    Xie, Panpan
    Abildlund, Morten T.
    Baekdal, Tine A.
    He, Xuemei
    Lyauk, Yassine K.
    Patted, Usha Rani H.
    Ning, Zu
    Shi, Aixin
    DIABETES OBESITY & METABOLISM, 2024, 26 (08): : 3068 - 3077